Specific antibodies to viruses HL-23 and BILN in the blood plasma of patients with acute myelogenous leukaemia and with potential preleukaemia.
Blood plasma samples from patients with acute myelogenous leukaemia (AML) or potential preleukaemia and from control subjects were tested for antibodies to the viruses HL-23 and BILN by membrane immunofluorescence. Of 15 patients with untreated AML, three, each having a low peripheral leucocyte count at the time of sampling, had detectable antibodies. Antibodies were present in the plasma of 5 out of 8 AML patients being in remission as a result of chemotherapy. In these cases, the antibody levels significantly exceeded those demonstrated in the untreated cases. Of 12 patients with potential preleukaemia, five proved to be positive. Of the 7 antibody-negative patients, four developed manifest leukaemia within 12-18 months after the first testing. The results are suggestive of a favourable prognostic role of the presence of the antibodies under study. In the majority of the antibody-positive AML and potential preleukameia cases antibodies were detectable to both components of the HL-23 virus. Of 30 control subjects, three had demonstrable antibodies to the BILN virus.
D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000032:analysis*; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000276:immunology; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011289:Preleukemia / Q000276:immunology*; D012190:Retroviridae / Q000276:immunology*
D000914:Antibodies, Viral